Net Loss per Share

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Notes to Financial Statements

Net Loss per Share

The Company calculates basic and diluted net loss per share using the weighted-average number of shares of common stock outstanding during the period.

When the Company is in a net loss position, it excludes from the calculation of diluted net loss per share all potentially dilutive stock options, preferred stock and warrants, and the diluted net loss per share is the same as the basic net loss per share for such periods.

The table below presents the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.

	As of March 31,
	2015		2014
Stock options		242,893		194,120
Redeemable convertible preferred stock		-		5,739,708
Preferred stock		238,156		-
Total		481,049		5,933,828

10. Net Loss per Share

The Company calculates basic and diluted net loss per share using the weighted-average number of shares of common stock outstanding during the period.

When the Company is in a net loss position, it excludes from the calculation of diluted net loss per share all potentially dilutive stock options, preferred stock and warrants, and the diluted net loss per share is the same as the basic net loss per share for such periods. If the Company was to be in a net income position, the weighted-average number of shares used to calculate the diluted net income per share would include the potential dilutive effect of in-the-money securities, as determined using the treasury stock method.

The table below presents the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.

	Years Ended December 31,
	2014		2013
Stock options		44,615		103,417
MabVax Series A redeemable convertible preferred stock		137,607		265,749
MabVax Series B redeemable convertible preferred stock		156,247		189,020
MabVax Series C-1 redeemable convertible preferred stock		412,444		—
Series B redeemable convertible preferred stock		102,895		—
Series A-1 preferred stock		742,658		—
Series C preferred stock		47,023		—
Total		1,643,489		558,186